A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 microg qd delivered by 2 different dry powder inhalers (Aerolizer and Almirall Inhaler), of the Fixed Dose Combination formoterol 12 microg + Aclidinium bromide 200 microg qd delivered by Almirall Inhaler, and of formoterol 12 microg bid delivered by Aerolizer, in moderate to severe Chronic Obstructive Pulmonary Disease Patients.

Trial Profile

A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 microg qd delivered by 2 different dry powder inhalers (Aerolizer and Almirall Inhaler), of the Fixed Dose Combination formoterol 12 microg + Aclidinium bromide 200 microg qd delivered by Almirall Inhaler, and of formoterol 12 microg bid delivered by Aerolizer, in moderate to severe Chronic Obstructive Pulmonary Disease Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Aclidinium bromide/formoterol; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top